The prognostic impact of age in patients with triple-negative breast cancer

被引:83
作者
Liedtke, Cornelia [1 ]
Hess, K. R. [2 ]
Karn, T. [3 ]
Rody, A. [1 ]
Kiesel, L. [4 ]
Hortobagyi, G. N. [5 ]
Pusztai, L.
Gonzalez-Angulo, A. M. [5 ]
机构
[1] Univ Schleswig Holstein, Dept Gynecol & Obstet, D-23538 Lubeck, Germany
[2] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA
[3] Goethe Univ Frankfurt, Dept Obstet & Gynecol, D-60054 Frankfurt, Germany
[4] Univ Munster, Dept Gynecol & Obstet, Munster, Germany
[5] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA
关键词
Triple-negative breast cancer; Age at diagnosis; Prognosis; Chemotherapy; Survival; SURVIVAL OUTCOMES; RECEPTOR; TRIAL; ESTROGEN; THERAPY;
D O I
10.1007/s10549-013-2461-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to assess the prognostic impact of age in patients with triple-negative breast cancer (TNBC). 1,732 patients with primary TNBC were analyzed. Five age cohorts (a parts per thousand currency sign30, 31-40, 41-50, 51-60, and > 60 years) at diagnosis were correlated with clinical/pathological parameters. Univariate and multivariate analyses were used to examine the effect of age on disease-free (DFS), distant disease-free (DDFS), and overall survival (OS). In patients with TNBC, increasing age at diagnosis was inversely correlated with tumor grade (P < 0.0001); likelihood of being non-Caucasian (P = 0.0001); likelihood of getting chemotherapy (P < 0.0001); and positively correlated with DFS (P = 0.0003); DDFS (P < 0.0001); and OS (P < 0.0001). The median DFS for patients 31-40 and older than 60 years was 4 years [95 % confidence interval (95 % CI) 2-5] and 8 years (95 % CI 5-14, respectively, P = 0.0003). The DDFS and OS were also statistically significantly shorter for younger patients. In multivariate analysis, tumor size, nodal stage, tumor grade, and age remained significant independent prognostic variables. Clinical characteristics of TNBC differ by age group, patients a parts per thousand currency sign40 years have poorer survival despite more aggressive systemic therapy.
引用
收藏
页码:591 / 599
页数:9
相关论文
共 19 条
[1]   Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer [J].
Aleskandarany, Mohammed A. ;
Green, Andrew R. ;
Benhasouna, Ahmed A. ;
Barros, Fabricio F. ;
Neal, Keith ;
Reis-Filho, Jorge S. ;
Ellis, Ian O. ;
Rakha, Emad A. .
BREAST CANCER RESEARCH, 2012, 14 (01)
[2]   Elucidating Prognosis and Biology of Breast Cancer Arising in Young Women Using Gene Expression Profiling [J].
Azim, Hatem A., Jr. ;
Michiels, Stefan ;
Bedard, Philippe L. ;
Singhal, Sandeep K. ;
Criscitiello, Carmen ;
Ignatiadis, Michail ;
Haibe-Kains, Benjamin ;
Piccart, Martine J. ;
Sotiriou, Christos ;
Loi, Sherene .
CLINICAL CANCER RESEARCH, 2012, 18 (05) :1341-1351
[3]   Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer [J].
Bayraktar, Soley ;
Hernadez-Aya, Leonel F. ;
Lei, Xiudong ;
Meric-Bernstam, Funda ;
Litton, Jennifer K. ;
Hsu, Limin ;
Hortobagyi, Gabriel N. ;
Gonzalez-Angulo, Ana M. .
CANCER, 2012, 118 (05) :1202-1211
[4]   Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations [J].
Bayraktar, Soley ;
Gutierrez-Barrera, Angelica M. ;
Liu, Diane ;
Tasbas, Tunc ;
Akar, Ugur ;
Litton, Jennifer K. ;
Lin, E. ;
Albarracin, Constance T. ;
Meric-Bernstam, Funda ;
Gonzalez-Angulo, Ana M. ;
Hortobagyi, Gabriel N. ;
Arun, Banu K. .
BREAST CANCER RESEARCH AND TREATMENT, 2011, 130 (01) :145-153
[5]   Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial [J].
Brufsky, Adam ;
Valero, Vicente ;
Tiangco, Beatrice ;
Dakhil, Shaker ;
Brize, Arija ;
Rugo, Hope S. ;
Rivera, Ragene ;
Duenne, Anja ;
Bousfoul, Naima ;
Yardley, Denise A. .
BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) :1067-1075
[6]   The triple negative paradox: Primary tumor chemosensitivity of breast cancer subtypes [J].
Carey, Lisa A. ;
Dees, E. Claire ;
Sawyer, Lynda ;
Gatti, Lisa ;
Moore, Dominic T. ;
Collichio, Frances ;
Ollila, David W. ;
Sartor, Carolyn I. ;
Graham, Mark L. ;
Perou, Charles M. .
CLINICAL CANCER RESEARCH, 2007, 13 (08) :2329-2334
[7]   RELATIVE WORTH OF ESTROGEN OR PROGESTERONE-RECEPTOR AND PATHOLOGIC CHARACTERISTICS OF DIFFERENTIATION AS INDICATORS OF PROGNOSIS IN NODE NEGATIVE BREAST-CANCER PATIENTS - FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT PROTOCOL B-06 [J].
FISHER, B ;
REDMOND, C ;
FISHER, ER ;
CAPLAN, R .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1076-1087
[8]   Breast Cancer in Young Women: Poor Survival Despite Intensive Treatment [J].
Fredholm, Hanna ;
Eaker, Sonja ;
Frisell, Jan ;
Holmberg, Lars ;
Fredriksson, Irma ;
Lindman, Henrik .
PLOS ONE, 2009, 4 (11) :A38-A46
[9]   Triple-negative breast cancer-current status and future directions [J].
Gluz, O. ;
Liedtke, C. ;
Gottschalk, N. ;
Pusztai, L. ;
Nitz, U. ;
Harbeck, N. .
ANNALS OF ONCOLOGY, 2009, 20 (12) :1913-1927
[10]   Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer [J].
Gonzalez-Angulo, Ana M. ;
Timms, Kirsten M. ;
Liu, Shuying ;
Chen, Huiqin ;
Litton, Jennifer K. ;
Potter, Jennifer ;
Lanchbury, Jerry S. ;
Stemke-Hale, Katherine ;
Hennessy, Bryan T. ;
Arun, Banu K. ;
Hortobagyi, Gabriel N. ;
Do, Kim-Anh ;
Mills, Gordon B. ;
Meric-Bernstam, Funda .
CLINICAL CANCER RESEARCH, 2011, 17 (05) :1082-1089